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Smoking induces airway hyperresponsiveness (AHR). Bronchial provocation with mannitol is
used to identify AHR in subjects with asthma. This study aimed to determine the
prevalence of airway hyperresponsiveness to mannitol in asymptomatic smokers compared
to non-smokers and to assess if airway responsiveness to mannitol changes after smoking
cessation.
Airway responsiveness to inhaled mannitol was measured in smokers (n ¼ 42), and non-
smokers (n ¼ 45). In smokers, the mannitol test was repeated 3 months after smoking
cessation.
Demographics including age, lung function and atopy status were similar for smokers and
non-smokers (p ¼ ns). Compared with non-smokers (2.2%), AHR to mannitol expressed by
X15% fall in FEV1 was significantly more common in smokers (26.2%) ðp ¼ 0:001Þ. The
provoking dose to induce a 15% fall in FEV1 (PD15), a measure of sensitivity, was median
[IQR] 291mg [207–377] in the 11 positive smokers. The response–dose ratio (RDR) (% fall in
FEV1/cumulative dose), a measure of reactivity, was significantly higher in smokers (0.013
[0.006–0.029]) compared with non-smokers (0.004 [0.002–0.007]), ðpo0:0001Þ. After
successful smoking cessation, the RDR decreased in most cases ðp ¼ 0:01Þ and only one
patient still recorded a X15% fall in FEV1. None of the patients with a negative mannitol
test turned positive, irrespective of the outcome of smoking cessation.
AHR to mannitol is quite common in smokers compared to non-smokers and decreases
significantly after smoking cessation. Thus, the mannitol test may be sensitive to non-
asthmatic inflammation of the airways.
& 2007 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
Medicine and Pulmonary Cell Research, University Hospital Basel, Petersgraben 4, 4031 Basel,
: +41 61 2654587.
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Smoking is the single most important risk factor for chronic
obstructive pulmonary disease (COPD).1–3 Cigarette smoke
has the capacity to damage the airways in a number of ways,
including direct toxicity to the epithelium, oxidative
damage, recruitment of inflammatory cells—particularly
neutrophils—and increased epithelial permeability.4,5 Sub-
sequently, smoking induced airway inflammation leads to
chronic respiratory symptoms in healthy adults, i.e. chronic
cough and sputum production, along with airflow limitation
in susceptible individuals.6,7
In non-asthmatic subjects, smoking has been shown to
induce airway hyperresponsiveness (AHR).8–11 According to
the provoking stimulus used, marked differences in the
reversibility and severity of AHR have been described. For
example, the prevalence of AHR to methacholine has been
reported to be higher in smokers than in ex-smokers,12–15
whereas the prevalence of AHR to histamine appears to be
similar in these two groups.16–18 The prevalence of AHR to
methacholine in both non-smokers and ex-smokers is
comparable, suggesting diminished responsiveness occurs
after smoking cessation.6 In contrast to methacholine, AHR
to histamine seems to be less reversible after smoking
cessation.6 Thus, smokers may also be expected to respond
to other mediators of inflammation such as prostaglandins
and leukotrienes.
In COPD, the degree of AHR is associated with the
subsequent annual decline in lung function19 and has been
identified as a major risk factor for the development of
respiratory symptoms in adults.20 Thus, AHR could be an
important measurement in determining the prognosis
of subjects susceptible to airway obstruction such as
smokers.
Bronchial provocation with a dry powder of mannitol has
been used as an indirect stimulus to measure AHR.
Inhalation of mannitol is associated with increased urinary
excretion of metabolites of the bronchoconstrictor–media-
tors prostaglandin D2 and leukotriene E4.
21 The response to
mannitol is inhibited by drugs that affect either the release
or effect of these and other mediators.22,23 The response to
mannitol is markedly reduced following treatment with
inhaled corticosteroids24,25 and, in the majority of well
controlled asthmatics, the response to mannitol increases
following back titration of steroids.26
The prevalence of AHR to mannitol in subjects who smoke
and the reversibility of this condition after smoking
cessation is not known. We wanted to know if AHR to an
indirect stimulus such as mannitol occurs in response to
airway inflammation caused by tobacco smoke and, if so,
does it alter with cessation of smoking. We studied the
airway sensitivity and reactivity to mannitol in asympto-
matic smokers and non-smokers and we assessed the
response after smoking cessation.
Methods
Subjects
A total of 97 participants were included in the study.
Subjects were recruited from the pulmonary outpatientclinic at the Basel University Hospital, Switzerland and by
advertisement in local newspapers. The group categorized
as ‘‘healthy non-smokers’’ ( ¼ non-smokers) consisted of 45
asymptomatic, life-long non-smokers without history of
asthma and a normal spirometry. The group categorized as
‘‘asymptomatic smokers’’ ( ¼ smokers) consisted of 42
current smokers (X10 cigarettes a day) willing to take part
in a smoking-cessation program. Subjects were eligible for
these two groups if they denied respiratory symptoms
(cough, phlegm, wheezing, and breathlessness) and did
not suffer from any known respiratory disease nor had a
respiratory infection within the preceding 2 months.
The institutional review board of the University Hospital
Basel approved the study protocol and all subjects gave
their written informed consent.
Study design
All subjects (smokers and non-smokers) visited the hospital
on at least two occasions, one week apart. During the first
visit, informed consent was obtained and lung function test
was performed. At the second visit, subjects underwent skin
prick-test, breath carbon monoxide (CO) measurement
(Micro Smokerlyzer, Bedfont Scientific, England) and man-
nitol challenge. Smokers entered a smoking cessation
program and had a follow-up visit at 3 months after the
effective quit day.
Lung function
Lung function [FVC (forced vital capacity), FEV1 (forced
expiratory value in 1 s), FEV1/FVC (forced expiratory value
in 1 s/forced vital capacity)] was measured using a spirom-
eter (Spirovit SP-10, Schiller, Switzerland) according to the
American Thoracic Society guidelines.27 The higher of two
values for FEV1, repeatable within 100ml, was recorded and
the percentage of predicted values was calculated.
Skin prick tests
Skin prick tests were performed using Phazet lances
(Pharmacia Diagnostic AB; Upsala, Sweden) on the volar
side of forearm. A standard panel, comprising the six most
common aeroallergens in this region: the mould Alternaria
tenuis, the mould Cladosporium homodendron, mixed grass,
cat dander, dog dander and the house dust mite Derma-
tophgoides pteronyssinus, (Trimedal, AG, Switzerland) was
used. Histamine 10mg/ml was used as positive control and a
saline/glycerol solution as negative control. Skin test
reactions (wheal size) were read along the long axis and
its perpendicular after 15min. A mean wheal size of 3mm or
greater was regarded as a positive response.28 Subjects
were considered atopic if they had a positive reaction toX1
of the eight allergens.
Mannitol challenge
Mannitol challenge was performed administering the spray-
dry mannitol powder in gelatin capsule form (AridolTM
Pharmaxis Ltd, Sydney, Australia), inhaled from a
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Table 1 Subject characteristics.
Non-smokers Smokers p-value
ðn ¼ 45Þ ðn ¼ 42Þ
Age (range) 39 (21–68) 43 (25–74) 0.096
Male gender (%) 27 (60%) 29 (69%) 0.379
Smoking, pack-yrs 0 30.2719.3 o0.001
Positive allergy test (%) 20 (44.4%) 20 (47.6%) 0.386
FEV1, L/s 3.570.7 3.570.7 0.755
FEV1, % predicted 9879 100713 0.531
FVC, L 4.370.8 4.470.9 0.631
FVC, % predicted 100710 104711 0.123
FEV1/FVC % 8377 8076 0.087
Numbers represent absolute numbers (%) or mean7SD. FEV1:
forced expiratory volume in 1 s; FVC: forced vital capacity.
D. Stolz et al.1472dry powder device (Osmohaler, Pharmaxis Ltd. French’s
Forrest, NSW, Australia) (RS01 Plastiape, Italy), as previously
described.29 FEV1 was measured 60 s after delivery of each
dose (5,10,20,40,80,160,160,160mg). If FEV1 decreased by
10%, the dose producing this fall was repeated. The test
continued until the FEV1 had fallen 15%, or the maximal
cumulative dose of 635mg had been administered.
The provoking dose to cause a 15% fall in FEV1 (PD15), a
measure of sensitivity to mannitol, was calculated by linear
interpolation of the relationship between the percentage
decrease in FEV1 and the cumulative dose of mannitol
required to provoke this decrease. The response–dose ratio
(RDR), a measure of reactivity, was calculated as the
percentage fall in FEV1 after the last dose, divided by the
cumulative dose, in milligrams. The 95% confidence interval
for a healthy non-asthmatic population has been reported to
be 0.0029%/mg (0.002, 0.004).30 The test result was
considered positive if FEV1 fell X 15%.
29 This value
represents the 95% CI of the value measured in healthy
subjects.30 Subjects were dissuaded from smoking for 6 h
before the test.
Smoking cessation program
The smoking cessation program consisted of six to eight
sessions within a period of 12 weeks. If necessary, nicotine
replacement products and bupropion (Zybans) was
prescribed. A quitter was defined as someone who refrained
from smoking for more than 3 months after the quit
day according to the personal reports and presented exhaled
breath CO-measurements p6 ppm 12 weeks after the
quit day. If a smoker failed to quit smoking at the defined
quit day, a second quit day would be set, and the evaluation
concerning the smoking status would be correspondingly
postponed to 12 weeks after the effective quit date.
All smokers, irrespective of the smoking status, were invited
to attend a follow-up visit to perform a mannitol challenge
test and CO-measurement 3 months after the effective
quit day.
Power calculation and data analysis
In the cross-sectional analysis, the difference in the
prevalence of AHR between smokers and non-smokers
was assessed. Assuming that AHR to mannitol would be
present in 30% of smokers and 5% of non-smokers, 40
smokers and 45 non-smokers would be needed to achieve a
5% significance levels with a power of 90%. To compare
differences in RDR between the study groups an
ANOVA (analysis of variance) with subsequent pairwise
comparisons was performed with the logarithmically
transformed data. Differences in dichotomous variables
were evaluated using the Chi-square test. All other
continuously distributed parameters were evaluated
using the non-parametric Mann–Whitney U test or Kruskal–
Wallis test, as appropriate. Calculations of PD15 were made
with the base-2 logarithm. Statistical analyses were per-
formed with the Statistical Package for Social Sciences (SSPS
Inc, version 13 for Windows). A p value of o0.05 was
considered significant. Values are expressed as means7SD,
unless stated otherwise.Results
Subject characteristics
Non-smokers and smokers characteristics are summarised in
Table 1. Non-smokers and smokers were similar concerning
age, gender distribution and allergy status. Mean exhaled
CO was 20.8711.6 ppm for smokers and 1.270.98 ppm for
non-smokers, respectively ðpo0:01Þ. Lung function para-
meters, including FVC (L and % predicted), FEV1 (L/s and %
predicted), and FEV1/FVC were also similar between the
two groups (p ¼ ns for all).
Prevalence of positivity to the mannitol test
A 15% fall in FEV1 in response to the mannitol challenge test
(mannitol positive) was found in one (2.2%) non-smoker as
compared to 11 (26.2%) smokers ðp ¼ 0:001Þ. The median
[IQR] provoking dose to induce the X15% fall in FEV1 (PD15)
was 291mg [207–377] for the 11 smokers and 92mg for the
one non-smoker. There was a significant difference
ðpo0:0001Þ in reactivity as measured by RDR between the
smokers and the non smokers: 0.013 [0.006–0.029] vs 0.004
[0.002–0.007] %/mg (Fig. 1). There was a significant
negative correlation between the reactivity to mannitol in
smokers and non-smokers expressed as log RDR and the %
predicted FEV1 (r ¼ 0:291, p ¼ 0:007, Spearman’s). The
presence of atopy was not associated with a higher
prevalence of airway responsiveness to mannitol
(p ¼ 0:549, Pearson chi-square).
Longitudinal effect of smoking cessation on
mannitol test positivity
At 3 months, abstinence from smoking was reported by 26
subjects (62%) and documented by CO-measurement in 22
subjects (52%). A second mannitol test, 3 months after the
quitting day, could be performed in 30 individuals of the 42,
of whom 22 were quitters and eight continued to smoke
(Fig. 2). In the remaining 12 cases, seven patients failed to
quit smoking and did not agree to repeat the examination;
four successful quitters withdrew consent for a second
challenge and one patient had left the country. Overall,
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30 (7%) of the subjects had a positive mannitol test after 3
months.
The FEV1% predicted before and RDR to mannitol three
months after smoking cessation are shown in Fig. 3A and B.
There was a small but significant decrease in the FEV1%
predicted after smoking cessation (99%714 to 94%713,
p ¼ 0:003) but the FEV1% predicted remained the same in
those who failed to quit smoking (105%710 and 103%711,
p ¼ 0:506). RDR markedly decreased after smoking cessation
in those who quit smoking ðpo0:0001Þ but it was not
significantly different in those who did fail to quit smoking
ðp ¼ 0:575Þ. Moreover, all but one of the subjects recording
a PD15 whilst a smoker failed to achieve a 15% fall after
successful smoking cessation ðp ¼ 0:02Þ. The one subject
with the persistent positive mannitol challenge after42 smokers
11 mannitol positive
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Figure 1 Response dose ratio % fall FEV1 per mg in a group of
45 non-smokers and 42 smokers. Horizontal lines represent the
geometric mean.successful smoking cessation showed a noticeably increase
in PD15 in the second test (95mg compared to 418mg). All 21
subjects with a negative mannitol test before smoking
cessation still had a negative second mannitol test,
irrespective of the smoking cessation outcome. The single
subject with a positive mannitol test, who was not able to
quit smoking, had a positive second mannitol test.Discussion
This prospective study showed a significantly higher pre-
valence of AHR to mannitol in asymptomatic smokers
compared with non-smokers. An important observation is
that both sensitivity, expressed by PD15, and reactivity,
expressed by RDR, to mannitol significantly decreased after
smoking cessation.
Mannitol is an osmotic stimulus that acts indirectly to
cause smooth muscle contraction and airway narrowing by
the release of mediators probably from mast cells and
eosinophils in the airways.21 Tobacco smoke is known to
produce acute and chronic irritation of the bronchial
mucosa, leading to a recruitment of inflammatory cells in
asymptomatic smokers.6 Smoking cessation leads to a
reduction in the number of macrophages and mast cells
both in bronchoalveolar lavage and in the bronchial
epithelium.31–34 Both mast cells and macrophages contain
mediators of bronchoconstriction including prostaglandin
D2, leukotrienes and histamine.
In this study, the prevalence of AHR to mannitol was 2.2%
in healthy non-smokers. In contrast, AHR to mannitol was
much more common in asymptomatic smokers with 26.2%,
recording a response considered to be in the asthmatic
range. Thus far, mannitol challenge has been used to
identify subjects with active asthmatic inflammation. There
are several studies in patients with asthma demonstrating
the benefits of treatment with inhaled steroids on respon-
siveness to mannitol.24,25 One in which seven of 18
asthmatics became negative to mannitol after 6–8 weeks
of treatment24 and one in which nine of 17 became14 quitters
7 mannitol negative
7 mannitol negative
8 quitters
1 smoker
2 drop out
7 smokers
10 drop out
1 mannitol positive
1 mannitol positive
14 mannitol negative
est 3 months after smoking cessation in a group of 42 smokers.
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Figure 3 (A) FEV1% predicted before and three months after smoking cessation. A ¼ before smoking cessation, B ¼ after smoking
cessation. (B) Response–dose-ratio to mannitol before and three months after smoking cessation. The arrow indicates the 95% CI for
RDR in healthy subjects.30 A ¼ Before smoking cessation, B ¼ after smoking cessation.
D. Stolz et al.1474unresponsive after 3 or 6 months of treatment.25 In a study
in well controlled asthmatics, 23 of 50 had no PD15 recorded
at the initial visit before down titration but only seven of
these remained unresponsive by the end of the study.35 All
but these seven subjects had an increase in their response to
mannitol over the course of the study. This suggests that
changes in asthmatic airway inflammation are being
detected by AHR to mannitol.
Our findings in this study suggest that, in addition to
providing information about AHR in asthmatics and its
change in response to inhaled steroids, mannitol may be
useful to identify AHR related to the inflammation of airway
injury in people who smoke but who are asymptomatic and
have normal lung function. Given that smokers will have
mast cells and macrophages in addition to neutrophils it is
not surprising to find that some demonstrate AHR to a
stimulus that causes release of bronchoconstricting
mediators. This has been demonstrated when using hyper-
tonic saline and AMP as stimuli particularly in smokers
with COPD.36
There are little longitudinal data analysing the effects of
smoking cessation on AHR in smokers without COPD. Both
Simonsson and Rolf37 and Buczko et al.38 reported that AHR
to methacholine and carbachol do not change after quitting,while Willemse et al. found an improvement of AHR to
methacholine and AMP after 1-year of smoking cessation.11
The present study is the first to compare mannitol challenge
before and after smoking cessation. After successful smok-
ing cessation, response to mannitol became negative in all
but one patient and RDR, that is the reactivity, decreased in
the majority of cases.
It is not known if the smooth muscle of subjects in our
study were responsive to challenge with a pharmacological
agonist but there are several possibilities as to why the
airways were less responsive to the mannitol. First, mannitol
responsiveness requires the presence of inflammatory cells,
particularly mast cells and eosinophils. In smokers there are
also macrophages. The reduction in number of these cells
and thus concentration of available mediators after smoking
cessation may result in reversibility of AHR. This concept
would be supported by the finding that AHR to adenosine-5-
monophosphate (AMP), another indirect stimulus that acts
through mast cell release of mediators, improves after
smoking cessation as well.34 This may explain why mannitol
hyperresponsiveness reverts to normal levels after smoking
cessation while AHR to inhaled agonists like methacholine
and histamine that act directly on the smooth muscle do
not.37–39 A second possibility is alteration of the properties
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airways causing injury and likely to result in plasma
exudation in response to epithelial cell injury.40 The
repeated exposure of the bronchial smooth muscle to
cytokines and growth factors in the plasma during this
restorative process may serve to increase the contractile
properties of the muscle.41 It is possible that cessation of
smoking resulted in a reduction in exposure to substances
affecting the muscle and, as a result, it was less responsive
to the same mediators. Although the smokers were
asymptomatic it is likely they did produce less mucus after
stopping smoking and thus there was less likelihood for the
mucus to amplify the airway narrowing effects of smooth
muscle contraction.42 Finally, exhaled nitric oxide levels
increase in response to cessation of smoking and this may
reflect an improved defence capability against bronchocon-
striction to inhaled mannitol.43 The findings in this study are
important because these subjects were asymptomatic and
had normal function.
Wise et al. have shown that AHR to methacholine
deteriorated over a 5-year period in patients with COPD,
particularly in persistent smokers as compared to quitters.19
In contrast, the Normative Aging Study found that smokers
who quit during a 3-year follow-up interval tended to have a
decline in AHR to methacholine, although the results did not
reach statistical significance.44 Our findings suggest that
AHR to mannitol decreases after 3-months of smoking
cessation in healthy smokers. Therefore, smoking cessation
may prevent further increase in AHR. As increased AHR
affects survival, particularly in smokers, early diagnosis of
AHR may have prognostic implications concerning COPD
development.45
A possible limitation of this study is the lack of other
measurements of airway inflammation. A reduction in
exhaled nitric oxide concentration (FeNO) is an indirect
index of a reduction in airway inflammation in asthma in
response to inhaled steroids. However, it is probably an
inappropriate index to use in this group because it is
reduced in smokers and paradoxically increases with
smoking cessation.43 Further, improvement in hyperrespon-
siveness after smoking cessation is not necessarily asso-
ciated with changes in sputum inflammatory cell counts as
assessed by induced sputum11 and mast cell numbers in
sputum are insufficient for useful determination. Therefore,
endobronchial biopsies would be needed to reliably evaluate
inflammation status of the airway.
In our study, 9/11 (81.8%) patients with a positive
mannitol challenge were successful quitters while just
14/31 (45.2%) subjects with a negative mannitol test were
able to quit smoking ðp ¼ 0:07Þ. Those who did quit smoking
became significantly less reactive to mannitol. It is possible
that the diagnosis of increased airway reactivity and
hyperresponsiveness, analogous to abnormal lung function
and CT scan findings,46 may act as a further motivation for
asymptomatic smokers to enhance abstinence. It is of
interest that those with the highest values for RDR were
the ones who were most successful in quiting smoking.
In summary, airway hyperresponsiveness to mannitol
occurs in some asymptomatic smokers with normal lung
function. Therefore, airway hyperresponsiveness to manni-
tol is not specific for asthmatic inflammation and maybe
useful for identifying AHR in those with airway injury andinflammation due to smoking. Both sensitivity and reactivity
to mannitol significantly decrease after successful smoking
cessation and long-term follow-up of these subjects might
prove useful.Acknowledgments
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